![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 09, 2021